Vasodilatory Therapeutics in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) CohortTracy Frech1*, Jessica Gordon2,3, Lorinda Chung4, Marcy Bolster5, Barbara Segal6, Ann Impens7, Lee Shapiro8, Avram Goldberg9, Vivien Hsu10, Chris T Derk11, Dinesh Khanna12, Monique Hinchcliff13, Maureen A Murtaugh14 and Virginia Steen15
- *Corresponding Author:
- Tracy Frech MD, MS
University of Utah, Salt Lake City, UT, USA
Tel: 801 581 4333
Fax: 801 581 6069
E-mail: [email protected]
Received Date: December 06, 2011; Accepted Date: February 13, 2012; Published Date: February 15, 2012
Citation: Frech T, Gordon J, Chung L, Bolster M, Segal B, et al. (2012) Vasodilatory Therapeutics in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort. Rheumatology S1:007. doi: 10.4172/2161-1149.S1-007
Copyright: © 2012 Frech T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry was designed to advance the understanding of the pathogenesis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). This registry provides the opportunity to examine both microvascular and macrovascular complications in SSc. In this manuscript we review SSc-PAH therapies and report on their use in the PHAROS registry.